Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1Phase 2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Sarcoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

Carboplatin 121pembrolizumab 119Pemetrexed 102Cisplatin 76Paclitaxel 56osimertinib 52Nivolumab 50Docetaxel 50durvalumab 47Specimen Handling 37Gemcitabine 34Magnetic Resonance Spectroscopy 33Radiosurgery 27Cetuximab 26130-nm albumin-bound paclitaxel 26atezolizumab 25Radiotherapy 20Ipilimumab 19Drug Therapy 19Bevacizumab 19cemiplimab 17amivantamab 17Taxes 16Ramucirumab 13alectinib 12tislelizumab 11lazertinib 11Leucovorin 11Fluorouracil 11Radiation 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × cobimetinib × 90 days × Clear all
NCT03178552 2026-06-05

B-FAST

Hoffmann-La Roche

Phase 2/3 Active not recruiting
1,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04302025 2026-05-22

NAUTIKA1

Genentech, Inc.

Phase 2 Recruiting
99 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03337698 2026-05-12

Morpheus Lung

Hoffmann-La Roche

Phase 1/2 Terminated
314 enrolled 31 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03202940 2026-05-08

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Massachusetts General Hospital

Phase 1/2 Active not recruiting
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡